6 completed, 2 withdrawn, 1 enrolling by invitation. 4 Phase 2, 4 Phase 3, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Withdrawn 2 |
| Phase 3 | 4 | Completed 2, Enrolling by invitation 1, Withdrawn 1 |
| Phase 4 | 2 | Completed 2 |
Follow eluxadoline: new trials by email Literature Review of eluxadoline trials Research Report on eluxadoline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigation of Eluxadoline for Diabetic Diarrhea Eluxadoline 100 mg - Diabetic Diarrhea, Diabetes | Phase 2 / Phase 3 | Withdrawn | Temple University | 2022-07-01 | 2023-05-06 | |
| A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) 25mg Eluxadoline, 100mg Eluxadoline - Irritable Bowel Syndrome | Phase 3 | Enrolling by invitation | AbbVie | 124 | 2021-08-13 | 2025-07-17 |
| Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence Eluxadoline 100 mg, Placebo - Fecal Incontinence, Accidental Bowel Leakage | Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2019-04-01 | 2019-07-25 | |
| Eluxadoline Bile Acid Malabsorption (BAM) Study Eluxadoline - Irritable Bowel Syndrome With Diarrhea | Phase 4 | Completed | Allergan | 24 | 2018-02-23 | 2021-05-19 |
| Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children Eluxadoline, Placebo - Irritable Bowel Syndrome | Phase 2 | Completed | AbbVie | 272 | 2017-11-15 | 2026-09-21 |
| Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use Eluxadoline, Placebo - Irritable Bowel Syndrome With Diarrhea | Phase 4 | Completed | Allergan | 346 | 2016-10-25 | 2019-02-15 |
| Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) Eluxadoline, Placebo - Irritable Bowel Syndrome | Phase 3 | Completed | Furiex Pharmaceuticals, Inc | 1146 | 2012-05-29 | 2018-07-30 |
| Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) Eluxadoline, Placebo - Irritable Bowel Syndrome | Phase 3 | Completed | Furiex Pharmaceuticals, Inc | 1282 | 2012-05-29 | 2018-09-04 |
| Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea Eluxadoline, Placebo - Irritable Bowel Syndrome | Phase 2 | Completed | Furiex Pharmaceuticals, Inc | 807 | 2010-04-28 | 2019-10-22 |
Irritable Bowel Syndrome (5) · Diarrhea (4) · Colonic Diseases (2) · Colonic Diseases, Functional (2) · Colonic Pseudo-Obstruction (2) · Digestive System Diseases (2) · Gastrointestinal Diseases (2) · Intestinal Diseases (2) · Signs and Symptoms, Digestive (2) · Diabetes Mellitus (1) · Encopresis (1) · Fecal Incontinence (1) · Urinary Incontinence, Urge (1)
Furiex Pharmaceuticals, Inc (3) · AbbVie (2) · Allergan (2) · Temple University (1) · University of North Carolina, Chapel Hill (1)
United States (8) · Canada (4) · United Kingdom (3) · Bulgaria (1) · Germany (1) · Hungary (1) · Netherlands (1) · Poland (1) · Puerto Rico (1) · Spain (1)
Anna Muslin (1) · Esther Jo (1) · Zachary Reichenbach, MD,PhD (1)
PMID 28167156, PMID 26789872, PMID 23583433, PMID 24813429
2017 (1)